Magnetar Financial’s Pacira BioSciences PCRX Stock Holding History

Magnetar Financial’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-65,370	Closed	-$2.62M	–	543
2023 Q2	$2.62M	Buy	+65,370	New	+$2.7M	0.06%	183
2021 Q3	–	Sell	-5,986	Closed	-$363	–	1472
2021 Q2	$363	Buy	+5,986	New	+$379K	﹤0.01%	978

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Magnetar Financial's PCRX Position: Q3 2023 in Review

Magnetar Financial sold out of Pacira BioSciences (PCRX) in Q3 2023, closing a stake of 65,370 shares — an estimated $2.62M sold.

Magnetar Financial first reported a position in PCRX in Q2 2021 and held it in 2 quarters. The position peaked at $2.62M in Q2 2023. 261 funds tracked by Wall St. Rank hold PCRX as of Q3 2023.

Magnetar Financial reported no remaining Pacira BioSciences position as of Q3 2023 after selling out during the quarter.
Magnetar Financial sold 65,370 Pacira BioSciences shares in Q3 2023, an estimated $2.62M.
Magnetar Financial first reported a position in Pacira BioSciences in Q2 2021 and held it in 2 quarters.
Magnetar Financial's Pacira BioSciences position peaked at $2.62M in Q2 2023.
261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2023.

Based on Magnetar Financial's 13F filing for Q3 2023, filed 14 Nov 2023.